WO2003032965A3 - Use of ace inhibitors for reducing type 2 diabetes in high risk patients - Google Patents

Use of ace inhibitors for reducing type 2 diabetes in high risk patients Download PDF

Info

Publication number
WO2003032965A3
WO2003032965A3 PCT/US2002/033213 US0233213W WO03032965A3 WO 2003032965 A3 WO2003032965 A3 WO 2003032965A3 US 0233213 W US0233213 W US 0233213W WO 03032965 A3 WO03032965 A3 WO 03032965A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
high risk
risk patients
reduce
increase
Prior art date
Application number
PCT/US2002/033213
Other languages
French (fr)
Other versions
WO2003032965A2 (en
Inventor
Salim Yusuf
Original Assignee
King Pharmaceuticals Res & Dev
Salim Yusuf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev, Salim Yusuf filed Critical King Pharmaceuticals Res & Dev
Priority to AU2002335843A priority Critical patent/AU2002335843A1/en
Publication of WO2003032965A2 publication Critical patent/WO2003032965A2/en
Publication of WO2003032965A3 publication Critical patent/WO2003032965A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to the use of an angiotensin-converting enzyme inhibitor, such as ramipril, to reduce or prevent Type 2 diabetes in high risk patients. The present invention also relates the use of an angiotensin-converting enzyme inhibitor, such as ramipril, to reduce the decline of β-cell function, increase islet blood flow, lower aldosterone secretion, lower renal potassium wasting, increase pancreatic β-cell perfusion, reduce insulin resistance in skeletal muscles, and increase insulin-mediated glucose disposal and uptake by skeletal muscles.
PCT/US2002/033213 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients WO2003032965A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002335843A AU2002335843A1 (en) 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34449501P 2001-10-17 2001-10-17
US60/344,495 2001-10-17

Publications (2)

Publication Number Publication Date
WO2003032965A2 WO2003032965A2 (en) 2003-04-24
WO2003032965A3 true WO2003032965A3 (en) 2003-11-27

Family

ID=23350759

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2002/011636 WO2003032963A2 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients
PCT/US2002/033213 WO2003032965A2 (en) 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011636 WO2003032963A2 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients

Country Status (7)

Country Link
EP (1) EP1438043A2 (en)
JP (1) JP2005531492A (en)
AU (1) AU2002335843A1 (en)
CA (1) CA2463682A1 (en)
IL (1) IL161388A0 (en)
MX (1) MXPA04003022A (en)
WO (2) WO2003032963A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure
WO2005020984A2 (en) * 2003-08-29 2005-03-10 Aaipharma Inc. Method of reducing the risk of oxidative stress
CA2661598A1 (en) * 2006-08-28 2008-03-06 Sanofi-Aventis Deutschland Gmbh Methods of lowering glucose levels
PL2970123T3 (en) 2013-03-14 2020-03-31 Amgen Inc. Salt of omecamtiv mecarbil and process for preparing salt
ES2884815T3 (en) * 2013-06-26 2021-12-13 Dong A St Co Ltd Composition for preventing or treating kidney diseases, comprising a DPP-IV inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331014A2 (en) * 1988-03-02 1989-09-06 THERA - Patent Verwaltungs-GmbH Use of ACE inhibitors in diabetes prophylaxis
DE4308504A1 (en) * 1993-03-18 1994-09-22 Knoll Ag New use of a combination of verapamil and trandolapril
WO2001015673A2 (en) * 1999-08-27 2001-03-08 Aventis Pharma Deutschland Gmbh Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
WO2001015674A2 (en) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331014A2 (en) * 1988-03-02 1989-09-06 THERA - Patent Verwaltungs-GmbH Use of ACE inhibitors in diabetes prophylaxis
DE4308504A1 (en) * 1993-03-18 1994-09-22 Knoll Ag New use of a combination of verapamil and trandolapril
WO2001015673A2 (en) * 1999-08-27 2001-03-08 Aventis Pharma Deutschland Gmbh Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
WO2001015674A2 (en) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.", LANCET. ENGLAND 22 JAN 2000, vol. 355, no. 9200, 22 January 2000 (2000-01-22), pages 253 - 259, XP002232380, ISSN: 0140-6736 *
BAKRIS GEORGE L ET AL: "ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure.", KIDNEY INTERNATIONAL, vol. 58, no. 5, November 2000 (2000-11-01), pages 2084 - 2092, XP001164193, ISSN: 0085-2538 *
CARLSSON P O ET AL: "Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats.", DIABETOLOGIA. GERMANY FEB 1998, vol. 41, no. 2, February 1998 (1998-02-01), pages 127 - 133, XP001148412, ISSN: 0012-186X *
GALLETTI FERRUCCIO ET AL: "Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS).", JOURNAL OF HYPERTENSION, vol. 17, no. 3, March 1999 (1999-03-01), pages 439 - 445, XP008014000, ISSN: 0263-6352 *
JANKA H U ET AL: "Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.", ARZNEIMITTEL-FORSCHUNG. GERMANY, WEST APR 1990, vol. 40, no. 4, April 1990 (1990-04-01), pages 432 - 435, XP001109698, ISSN: 0004-4172 *
KEILANI T ET AL: "Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium.", JOURNAL OF CLINICAL PHARMACOLOGY. UNITED STATES JAN 1995, vol. 35, no. 1, January 1995 (1995-01-01), pages 87 - 97, XP008021110, ISSN: 0091-2700 *
KRUETZFELDT JAN ET AL: "Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 362, no. 1, July 2000 (2000-07-01), pages 1 - 6, XP001148413, ISSN: 0028-1298 *
MUTSCHLER: "Arzneimittelwirkungen", WVG, STUTTGART, XP002232383 *
YUSUF S ET AL: "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.", THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 20 JAN 2000, vol. 342, no. 3, 20 January 2000 (2000-01-20), pages 145 - 153, XP008013952, ISSN: 0028-4793 *
YUSUF S ET AL: "RAMIPRIL AND THE DEVELOPMENT OF DIABETES", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 286, no. 15, 17 October 2001 (2001-10-17), pages 1882 - 1885, XP008013945, ISSN: 0098-7484 *

Also Published As

Publication number Publication date
WO2003032963A3 (en) 2003-12-24
WO2003032963A2 (en) 2003-04-24
WO2003032965A2 (en) 2003-04-24
JP2005531492A (en) 2005-10-20
IL161388A0 (en) 2004-09-27
EP1438043A2 (en) 2004-07-21
MXPA04003022A (en) 2004-07-05
AU2002335843A1 (en) 2003-04-28
CA2463682A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
NZ515902A (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes
WO2004032836A3 (en) Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
NO20044889L (en) Inhibitors of serine proteases, especially HCV NS3-NS4A protease
AU2003201274A1 (en) Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
WO2004037169A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003082817A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
GB0213612D0 (en) Organic compounds
CA2368186A1 (en) Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
WO2004050022A8 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
WO2004112701A3 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EA200700020A1 (en) INFUSION AND INJECTION SOLUTION OF LEVODOPA
MXPA04003825A (en) Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system.
WO2004069162A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004064778A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103276A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PL376822A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2006044556A3 (en) Dual inhibitors of lipoxygenase for treating diabetes
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004028516A3 (en) Compositions for the inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
WO2003032965A3 (en) Use of ace inhibitors for reducing type 2 diabetes in high risk patients
CA2481593A1 (en) Biologically stable liquid composition of fviii, of vwf or of fviii/vwf complex of human origin
AU2003288793A1 (en) Pharmaceutical compound containing silymarin and carbopol®, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP